DBV Technologies reported $215.4M in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.79B 51.25M Sep/2026
Alnylam Pharmaceuticals USD 7.99B 2.44B Sep/2026
Amarin USD 634.08M 9.72M Sep/2026
BioCryst Pharmaceuticals USD 591.07M 33.22M Sep/2026
BioMarin Pharmaceutical USD 11.57B 154.21M Sep/2026
DBV Technologies USD 215.4M 7.8M Sep/2026
Galectin Therapeutics USD 27.65M 1.76M Jun/2024
Halozyme Therapeutics USD 3.47B 895.94M Sep/2026
Incyte USD 7.29B 585.39M Sep/2026
Insmed USD 2.23B 123.49M Sep/2026
Ionis Pharmaceuticals USD 2.91B 81.91M Sep/2026
Neurocrine Biosciences USD 5.63B 268.3M Sep/2026
PTC Therapeutics USD 3.21B 42.76M Sep/2026
Sarepta Therapeutics USD 3.17B 22.45M Sep/2026
Ultragenyx Pharmaceutical USD 1.19B 77M Sep/2026
United Therapeutics USD 7.03B 186M Sep/2026